Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
RESEARCH TOOLSreports
Holding DE:9IP1?
Track your performance easily
9IP1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.54 - €29.42
Previous Close€10.54
Volume0.00
Average Volume (3M)47.00
Market Cap
€1.18B
Enterprise Value€978.57M
Total Cash (Recent Filing)$235.66M
Total Debt (Recent Filing)$25.64M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 06, 2025EPS Estimate
-€0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.54
Shares Outstanding91,157,085
10 Day Avg. Volume2
30 Day Avg. Volume47
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.91
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-425.46
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
€42.38Price Target Upside302.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Rocket Pharmaceuticals News
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Danon Disease and PKD Studies
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe public offering results in gross proceeds of $165 million with an underwriter’s option for additional shares.
Gene Therapy SuccessThere is a high 65-75% chance of success for the pivotal Phase II study for Danon heart disease, which supports regulatory filings thereafter.
Positive Clinical DataAll evaluable patients from the Phase I study of RP-A501 in Danon disease remain alive and transplant-free, surpassing the indication's typical natural history.
Bears Say
Financial PerformanceApproval for leukocyte adhesion deficiency type I treatment has been delayed to 2025, impacting financial expectations.
Operational DelaysInitiation of RP-L301's pivotal study has been delayed until 2025.
Stock ValuationUpdating the model for the offering lowers the price target from $44 to $40.
---
9IP1 FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was €10.54 and its highest was €29.42 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Currently, no data Available
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 73 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -€0.681 earnings per share for the quarter, beating the consensus estimate of -€0.719 by €0.038.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -€0.69.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 106,337,080 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -€0.681 in its last earnings report, beating expectations of -€0.719. Following the earnings report the stock price went down -2.376%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 76M.
---
Rocket Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€42.38 (302.06% Upside)
€42.38 (302.06% Upside)
Blogger Sentiment
Bullish
DE:9IP1 Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $302.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.56%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
-34.25%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
9IP1 Stock 12 Month Forecast
Average Price Target
€42.38
▲(302.06% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Bluebird Bio
―
Sangamo Biosciences
―
Best Analysts Covering 9IP1
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+12.42%
reiterated a buy rating last month
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +12.42% per trade.
---